Improvements in liquid biopsy techniques offer a more holistic view of cancer
Published on August 11, 2016
By Paul W. Dempsey, PhD
In the world of cancer diagnosis and monitoring, liquid biopsy technologies have the potential to be truly revolutionary. It has been known for many years that tumors shed cells, cell fragments, and DNA fragments into the bloodstream. But it is the pairing of these biological mechanisms with modern sample preparation and analysis platforms such as digital polymerase chain reaction (dPCR) or next-generation sequencing that is suddenly making it conceivable to analyze vanishingly rare cancer-derived events in a thicket of normal cells or DNA.